Regulation of cancer using natural compounds and/or diet

Patent metadata

Field	Value
Publication number	US-11666549-B2
Application number	US-202016860153-A
Country	US
Kind code	B2
Filing date	Apr 28, 2020
Priority date	Mar 14, 2013
Publication date	Jun 6, 2023
Grant date	Jun 6, 2023

Abstract

The current invention is directed to a treatment of a proliferative disease comprising administering to a subject in need of such treatment, a composition comprising epigallocatechin-3-gallate (EGCG), curcumin, glucosinolates and, optionally Daikon radish sprout, alone or in combination with providing a ketogenic diet or a modified ketogenic diet to the subject. The invention also provides a composition comprising medium chain triglycerides, Epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as glucoraphanin and its breakdown product sulforaphane, (SFN) (which are found at high levels in broccoli sprouts or sprouts of other cruciferous vegetables), and, optionally Daikon radish sprout.

First claim

We claim:

1. A method of treating a subject for a proliferative disease, comprising administering to the subject having the proliferative disease, each of (i), (ii), and (iii):
(i) a composition comprising epigallocatechin-3-gallate,
(ii) a composition comprising curcumin, and
(iii) a composition comprising glucoraphanin and/or sulforaphane (SFN),
wherein (i), (ii), and (iii) are administered individually or as a single composition, and, optionally, providing a modified ketogenic diet or a ketogenic diet to the subject, wherein the proliferative disease is cancer selected from the group consisting of brain cancer, breast cancer, colon cancer, and lung cancer.

2. The method of claim 1 , further comprising administering to the subject Daikon radish sprout, a Daikon radish sprout extract or a powder of said extract or the Daikon radish sprout.

3. The method of claim 1 , wherein the method further comprises an additional therapy or therapies to treat the proliferative disease.

4. The method of claim 3 , wherein the additional therapy or therapies to treat the proliferative disease are selected from radiotherapy, chemotherapy, surgery, immunotherapy, and/or monoclonal antibody therapy.

5. The method of claim 4 , wherein the additional therapy or therapies comprise(s) administering one or more compounds selected from abiraterone acetate, methotrexate, paclitaxel albumin-stabilized nanoparticle formulation, a combination of doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, and dacarbazine, a combination of doxorubicin hydrochloride, bleomycin sulfate vincristine sulfate, and etoposide, a combination of doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide, a combination of doxorubicin hydrochloride and cyclophosphamide, a regimen of a combination of doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel, brentuximab vedotin, a combination of cytarabine, daunorubicin, and etoposide, doxorubicin hydrochloride, fluorouracil, everolimus, imiquimod, aldesleukin, alemtuzumab, pemetrexed disodium, palonosetron hydrochloride, chlorambucil, chlorambucil, aminolevulinic acid, anastrozole, aprepitant, anastrozole, exemestane, nelarabine, arsenic trioxide, ofatumumab, asparaginase Erwinia chrysanthemi , bevacizumab, axitinib, azacitidine, a regimen of bleomycin, etoposide, doxorubicin hydrochloride, cyclophosphamide, vincristine, procarbazine, and prednisone, bendamustine hydrochloride, a combination of bleomycin, etoposide, and cisplatin, bevacizumab, bexarotene, tositumomab and I 131 iodine tositumomab, bleomycin, bortezomib, bosutinib, brentuximab vedotin, cabazitaxel, cabozantinib-S-malate, a combination of cyclophosphamide, doxorubicin hydrochloride, and fluorouracil, alemtuzumab, irinotecan hydrochloride, capecitabine, a combination of oxaliplatin and capecitabine, carboplatin, a combination of carboplatin and paclitaxel, carfilzomib, lomustine, daunorubicin hydrochloride, recombinant HPV bivalent vaccine, cetuximab, chlorambucil, a combination of chlorambucil and prednisone, a combination of cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, cisplatin, cyclophosphamide, clofarabine, a combination of cyclophosphamide, methotrexate, and fluorouracil, cabozantinib-S-Malate, a combination of cyclophosphamide, oncovin, procarbazine, and prednisone, dactinomycin, crizotinib, a combination of cyclophosphamide, vincristine sulfate, and prdnisone, cyclophosphamide, ifosfamide, cytarabine, liposomal cytarabine, cyclophosphamide, dacarbazine, decitabine, dactinomycin, dasatinib, daunorubicin hydrochloride, degarelix, denileukin, denosumab, liposomal cytarabine, liposomal cytarabine, dexrazoxane hydrochloride, docetaxel, doxorubicin hydrochloride liposome, doxorubicin hydrochloride, doxorubicin hydrochloride liposome, dacarbazine, fluorouracil, rasburicase, epirubicin hydrochloride, oxaliplatin, eltrombopag olamine, aprepitant, enzalutamide, epirubicin hydrochloride, a combination of etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride, cetuximab, eribulin mesylate, vismodegib, erlotinib hydrochloride, etoposide phosphate, etoposide, doxorubicin hydrochloride liposome, everolimus, raloxifene hydrochloride, exemestane, toremifene, fulvestrant, a combination of 5-fluorouracil, epiodoxorubicin, and cyclophosphamide, letrozole, filgrastim, fludarabine phosphate, fluorouracil, methotrexate, a combination of calcium folinate, 5-fluorouracil, and irinotecan hydrochloride, and bevacizumab, a, a combination of leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, a combination of leucovorin calcium, fluorouracil, and oxaliplatin, pralatrexate, a combination of fluorouracil and leucovorin calcium, recombinant HPV quadrivalent vaccine, gefitinib, gemcitabine hydrochloride, a combination of gemcitabine and cisplatin, gemtuzumab ozogamicin, imatinib mesylate, glucarpidase, eribulin mesylate, trastuzumab, human papillomavirus bivalent vaccine (recombinant), human papillomavirus quadrivalent vaccine (recombinant), topotecan hydrochloride, ibritumomab tiuxetan, a combination of carboplatin, etoposide, and ifosfamide, ponatinib hydrochloride, ifosfamide, imatinib mesylate, imiquimod, axitinib, ipilimumab, gefitinib, irinotecan hydrochloride, romidepsin, ixabepilone, ruxolitinib phosphate, cabazitaxel, raloxifene hydrochloride, palifermin, carfilzomib, lapatinib ditosylate, lenalidomide, letrozole, leucovorin calcium, chlorambucil, leuprolide acetate, aminolevulinic acid, chlorambucil, doxorubicin hydrochloride liposome, liposomal cytarabine, lomustine, leuprolide acetate, vincristine sulfate liposome, procarbazine hydrochloride, mechlorethamine hydrochloride, mesna, temozolomide, methotrexate, mitomycin C, a regimen of mechlorethamine, vincristine, procarbazine, and prednisone, plerixafor, mechlorethamine hydrochloride, azacitidine, gemtuzumab ozogamicin, vinorelbine tartrate, nelarabine, cyclophosphamide, filgrastim, sorafenib tosylate, nilotinib, tamoxifen citrate, romiplostim, ofatumumab, omacetaxine, mepesuccinate, pegaspargase, denileukin diftitox, oxaliplatin, palifermin, palonosetron hydrochloride, panitumumab, carboplatin, pazopanib hydrochloride, pegaspargase, pemetrexed disodium, pertuzumab, cisplatin, plerixafor, ponatinib hydrochloride, pralatrexate, prednisone, procarbazine hydrochloride, aldesleukin, denosumab, eltrombopag olamine, sipuleucel-T, raloxifene hydrochloride, rasburicase, a combination of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincritstine sulfate, and prednisone, a combination of rituximab, cyclophosphamide, vincritstine sulfate, and prednisone, recombinant HPV bivalent vaccine, recombinant HPV, quadrivalent vaccine, regorafenib, lenalidomide, methotrexate, rituximab, romidepsin, romiplostim, daunorubicin hydrochloride, ruxolitinib phosphate, talc, sipuleucel-T, sorafenib tosylate, dasatinib, a combination of mechlorethamine, doxorubicin hydrochloride, vinblastine sulfate, vincristine sulfate, bleomycin, etoposide phosphate, and prednisone, sterile talc powder, regorafenib, sunitinib malate, thalidomide, omacetaxine mepesuccinate, tamoxifen citrate, cytarabine, erlotinib hydrochloride, bexarotene, nilotinib, paclitaxel, docetaxel, temozolomide, thalidomide, topotecan hydrochloride, toremifene, temsirolimus, dexrazoxane hydrochloride, bendamustine hydrochloride, lapatinib ditosylate, vandetanib, a combination of vincristine sulfate, doxorubicine hydrochloride, methotrexate, and prednisone, panitumumab, a combination of etoposide, ifosfamide, and cisplatin, vinblastine sulfate, bortezomib, vemurafenib, leuprolide acetate, azacitidine, vincristine sulfate, vincristine sulfate liposome, vinorelbine tartrate, vismodegib, glucarpidase, vorinostat, pazopanib hydrochloride, le

Assignees

• Univ Florida
• Univ Florida

Inventors

• Reynolds Brent Allan
• Deleyrolle Loic Pierre

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A23L29/055

  containing sulfur as heteroatom · CPC title

• A61K31/7028

  Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages · CPC title

• A61K31/26

  Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters · CPC title